Cannabis Bioscience International Holdings (CBIH) Ratios
44 Followers
Cannabis Bioscience International Holdings Ratios
CBIH's free cash flow for Q3 2025 was $-14.60K. For the 2025 fiscal year, CBIH's free cash flow was increased by $0.00 and operating cash flow was $-14.60K. See a summary of the company’s cash flow.
| Ratios | May 25 | May 24 | May 23 | May 22 | May 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.03 | 0.02 | 0.05 | 0.22 | 0.29 |
| Quick Ratio | 0.03 | 0.02 | 0.05 | 0.22 | 0.29 |
| Cash Ratio | 0.01 | 0.00 | 0.02 | 0.14 | 0.22 |
| Solvency Ratio | -0.43 | -0.58 | -1.57 | -1.88 | -0.35 |
| Operating Cash Flow Ratio | -0.35 | -0.54 | -2.37 | -3.83 | -2.71 |
| Short-Term Operating Cash Flow Coverage | -1.99 | -2.98 | -6.71 | -6.14 | -3.17 |
| Net Current Asset Value | $ -1.17M | $ -1.11M | $ -615.59K | $ -421.35K | $ -395.34K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 13.18 | 7.64 | 8.99 | 3.52 | 2.84 |
| Debt-to-Equity Ratio | -0.36 | -0.40 | -0.66 | -1.07 | -1.40 |
| Debt-to-Capital Ratio | -0.57 | -0.68 | -1.93 | 14.97 | 3.48 |
| Long-Term Debt-to-Capital Ratio | -0.27 | -0.30 | -0.73 | -2.08 | -2.78 |
| Financial Leverage Ratio | -0.03 | -0.05 | -0.07 | -0.30 | -0.49 |
| Debt Service Coverage Ratio | -0.97 | -1.53 | -3.83 | -4.38 | -0.54 |
| Interest Coverage Ratio | -2.34 | -2.94 | -10.81 | -17.40 | -2.59 |
| Debt to Market Cap | 64.59 | 66.24 | 96.18 | 118.38 | 115.78 |
| Interest Debt Per Share | 0.06 | 0.06 | 0.05 | 0.05 | 0.06 |
| Net Debt to EBITDA | -1.21 | -0.88 | -0.42 | -0.43 | -3.43 |
| Profitability Margins | |||||
| Gross Profit Margin | 86.76% | 81.68% | 70.50% | 78.25% | 99.52% |
| EBIT Margin | -121.58% | -195.36% | -297.20% | -388.01% | -15.09% |
| EBITDA Margin | -110.73% | -199.78% | -285.72% | -388.01% | -14.61% |
| Operating Profit Margin | -139.05% | -195.36% | -310.38% | -413.09% | -15.09% |
| Pretax Profit Margin | -181.12% | -261.75% | -337.40% | -411.75% | -20.91% |
| Net Profit Margin | -181.12% | -261.75% | -325.91% | -411.75% | -20.91% |
| Continuous Operations Profit Margin | -181.12% | -261.75% | -325.91% | -411.75% | -20.91% |
| Net Income Per EBT | 100.00% | 100.00% | 96.60% | 100.00% | 100.00% |
| EBT Per EBIT | 130.25% | 133.98% | 108.70% | 99.67% | 138.58% |
| Return on Assets (ROA) | -1721.52% | -1139.47% | -2380.20% | -805.48% | -107.07% |
| Return on Equity (ROE) | 47.17% | 60.36% | 174.52% | 245.17% | 52.90% |
| Return on Capital Employed (ROCE) | 46.10% | 58.94% | 287.40% | 782.37% | 297.13% |
| Return on Invested Capital (ROIC) | 56.68% | 75.71% | 470.88% | -3435.97% | -94.51% |
| Return on Tangible Assets | -1721.52% | -1139.47% | -2380.20% | -805.48% | -107.07% |
| Earnings Yield | -8535.55% | -10521.57% | -25763.24% | -27352.17% | -4829.79% |
| Efficiency Ratios | |||||
| Receivables Turnover | 19.51 | 12.36 | 30.03 | 12.21 | 57.29 |
| Payables Turnover | 0.40 | 0.23 | 0.84 | 0.69 | 0.22 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 108.42 | 6.98 | 13.25 | 3.57 | 8.09 |
| Asset Turnover | 9.51 | 4.35 | 7.30 | 1.96 | 5.12 |
| Working Capital Turnover Ratio | -0.34 | -0.41 | -1.17 | -1.40 | -7.40 |
| Cash Conversion Cycle | -894.50 | -1540.06 | -422.56 | -502.49 | -1630.92 |
| Days of Sales Outstanding | 18.71 | 29.54 | 12.15 | 29.91 | 6.37 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 913.21 | 1569.60 | 434.72 | 532.40 | 1637.29 |
| Operating Cycle | 18.71 | 29.54 | 12.15 | 29.91 | 6.37 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.03 | -0.05 | -0.09 | -0.11 | -0.06 |
| Free Cash Flow Per Share | -0.03 | -0.05 | -0.09 | -0.11 | -0.06 |
| Dividend Paid and CapEx Coverage Ratio | -82406.76 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -82406.76 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.78 | -1.10 | -2.34 | -2.21 | -1.20 |
| Operating Cash Flow to Sales Ratio | -1.09 | -1.93 | -2.88 | -3.98 | -0.67 |
| Free Cash Flow Yield | -5126.54% | -7743.75% | -22783.71% | -26441.62% | -15392.26% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.01 | -0.01 | -0.00 | -0.00 | -0.02 |
| Price-to-Sales (P/S) Ratio | 0.02 | 0.02 | 0.01 | 0.02 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.02 | -0.01 | -0.00 | -0.00 | -0.01 |
| Price-to-Operating Cash Flow Ratio | -0.02 | -0.01 | -0.00 | -0.00 | -0.01 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 |
| Enterprise Value Multiple | -1.23 | -0.89 | -0.43 | -0.43 | -3.46 |
| Enterprise Value | 413.71K | 442.31K | 385.03K | 358.15K | 384.78K |
| EV to EBITDA | -1.23 | -0.89 | -0.43 | -0.43 | -3.46 |
| EV to Sales | 1.37 | 1.78 | 1.22 | 1.67 | 0.51 |
| EV to Free Cash Flow | -1.26 | -0.92 | -0.42 | -0.42 | -0.76 |
| EV to Operating Cash Flow | -1.26 | -0.92 | -0.42 | -0.42 | -0.76 |
| Tangible Book Value Per Share | -0.11 | -0.10 | -0.06 | -0.04 | -0.04 |
| Shareholders’ Equity Per Share | -0.11 | -0.10 | -0.06 | -0.04 | -0.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| Revenue Per Share | 0.03 | 0.02 | 0.03 | 0.03 | 0.09 |
| Net Income Per Share | -0.05 | -0.06 | -0.10 | -0.11 | -0.02 |
| Tax Burden | 1.00 | 1.00 | 0.97 | 1.00 | 1.00 |
| Interest Burden | 1.49 | 1.34 | 1.14 | 1.06 | 1.39 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 1.38 | 2.61 | 3.64 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 |
| Income Quality | 0.60 | 0.74 | 0.88 | 0.97 | 3.19 |
Currency in USD
